Literature DB >> 2148336

Imipramine and weight gain during the treatment of recurrent depression.

E Frank1, D J Kupfer, C M Bulik, J A Levenson.   

Abstract

Weight change was examined in 128 depressed outpatients treated successfully with an average dose of 215 mg imipramine and then continued on that treatment regimen for 5 additional months, an average duration of over 33 weeks. More than half the patients experienced a change in weight of 5% or less and only 13.3% experienced a gain of greater than 10%. While males and females did not differ in their pattern of change during acute treatment, females experienced a greater percent change (P less than 0.06) and change in body mass index (P = 0.05) during continuation treatment. The clinical implications of these findings are discussed, especially with respect to the extreme group.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2148336     DOI: 10.1016/0165-0327(90)90140-4

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  6 in total

Review 1.  The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications.

Authors:  Roger S McIntyre; Ka Young Park; Candy W Y Law; Farah Sultan; Amanda Adams; Maria Teresa Lourenco; Aaron K S Lo; Joanna K Soczynska; Hanna Woldeyohannes; Mohammad Alsuwaidan; Jinju Yoon; Sidney H Kennedy
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

2.  AGN-2979, an inhibitor of tryptophan hydroxylase activation, does not affect serotonin synthesis in Flinders Sensitive Line rats, a rat model of depression, but produces a significant effect in Flinders Resistant Line rats.

Authors:  Kazuya Kanemaru; Kyoko Nishi; Mirko Diksic
Journal:  Neurochem Int       Date:  2009-05-20       Impact factor: 3.921

3.  Weight gain, obesity, and psychotropic prescribing.

Authors:  Nikhil Nihalani; Thomas L Schwartz; Umar A Siddiqui; James L Megna
Journal:  J Obes       Date:  2011-01-17

Review 4.  Cardiometabolic effects of psychotropic medications.

Authors:  Oluchi Abosi; Sneha Lopes; Samantha Schmitz; Jess G Fiedorowicz
Journal:  Horm Mol Biol Clin Investig       Date:  2018-01-10

Review 5.  Medications that cause weight gain and alternatives in Canada: a narrative review.

Authors:  Sean Wharton; Lilian Raiber; Kristin J Serodio; Jasmine Lee; Rebecca Ag Christensen
Journal:  Diabetes Metab Syndr Obes       Date:  2018-08-21       Impact factor: 3.168

6.  Comparing the effects of fluoxetine and imipramine on total cholesterol, triglyceride, and weight in patients with major depression.

Authors:  Esmaeil Shahsavand Ananloo; Padideh Ghaeli; Mohammad-Zaman Kamkar; Majid Sadeghi
Journal:  Daru       Date:  2013-01-05       Impact factor: 3.117

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.